Abstract
Target drug delivery for therapeutic pharmaceuticals in a carcinogenic environment is becoming more popular because of its benefits, such as avoiding systemic adverse effects, high productivity and low-cost competence. Herein, in this study Evodiamine-albumin nanoparticles (EANPs) were incorporated into 3D porous polycaprolactone (PCL) scaffolds for sustained release, aiming to evaluate their potential as an effective and improved treatment for cervical cancer. Morphological and physicochemical analyses confirmed successful nanoparticle integration and drug amorphization. EANP-loaded scaffolds exhibited controlled drug release for 8 days, with increasing concentrations inducing dose-dependent cytotoxicity and apoptosis in HeLa cancer cells. These findings suggest EANP-loaded PCL scaffolds hold significant potential for improved cervical cancer treatment through sustained drug delivery and enhanced efficacy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
